News
Public · Published
Buy Jupiter Life Line Hospitals; target of Rs 330: Prabhudas Lilladher
Prabhudas Lilladher maintained a BUY rating on Jupiter Life Line Hospitals but lowered its target price to Rs 330 from Rs 360 per share. The broker's Q2 report showed consolidated EBITDA, which means earnings before interest, tax, depreciation and amortisation, grew 16% year on year to Rs 1.1bn.
Published:
Updated:
What happened
Prabhudas Lilladher maintained a BUY rating on Jupiter Life Line Hospitals but lowered its target price to Rs 330 from Rs 360 per share. The broker's Q2 report showed consolidated EBITDA, which means earnings before interest, tax, depreciation and amortisation, grew 16% year on year to Rs 1.1bn.
Confirmed
Global impact / market context
A lower target price signals the broker trimmed its valuation even while keeping a positive rating. Investors holding the stock face a gap between the new target and the earlier one, so they must judge whether slower expected gains still justify owning the shares.
Analyst inference
The report links hospital earnings to occupancy, pricing and new beds. Growth at Pune and Indore is expected to come from higher occupancy spreading fixed costs, while Thane relies more on price increases. Expansion into densely populated western areas is expected to support medium-term growth.
Analyst inference
What to watch
- Dombivli unit losses fell sharply and the broker expects the unit to improve further as occupancy and case mix rise, which means treating sicker or more complex cases. Confirmed
- The broker projects roughly 30 to 40 new beds at Thane, where growth is expected to remain largely price led rather than driven by more patients. Proposed
- Watch whether hospital revenue and EBITDA compound near 20% and 16% respectively, since missing those paths would undercut the valuation behind the Rs 330 target. Analyst inference
Evidence
- Original source link unavailable